
Glytec Stock
Glytec is the pioneer of personalized digital therapeutics, enabling best practices for insulin management.
Sign up today and learn more about Glytec Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Glytec Stock
Glytec is the pioneer of personalized digital therapeutics, enabling best practices for inpatient and outpatient insulin management. The company’s patented and FDA-cleared software-as-a-medical-device solutions improve the safety and health of people with diabetes and make insulin a more effective medication option for millions who are unable to achieve their treatment goals. Glytec combines evidence-based decision support technologies with expert clinical services to optimize basal and bolus insulin therapies in the hospital and at home, leading to reductions in hypoglycemia and other complications as well as avoidable ED visits, hospitalizations, readmissions and drug waste. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information visit www.glytecsystems.com.
Funding History
July 2009 | $131K |
---|---|
January 2011 | $100K |
June 2011 | $2.0M |
September 2011 | $8.3M |
November 2012 | $4.0M |
July 2013 | $3.5M |
November 2013 | $3.0M |
Management
VP Quality Initiatives
Raymie McFarland
VP Client Development
Scott Rape
President and CEO
Bob Leonard
Chief Medical Officer
Andrew Rhinehart
VP Clinical Services
Melanie Mabrey
Chief Financial Officer
John Beneke
SVP Research & Development
Robby Booth
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase